Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus improvement in body weight with combination tirzepatide plus ixekizumab vs. ixekizumab monotherapy, data show.Data from TOGETHER-PsO — a 52-week, phase 3b, randomized, double-blind, open-label study — demonstrated that participants who received combination

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus improvement in body weight with combination tirzepatide…

Adding tirzepatide helped patients shed pounds, improved complete skin clearance rates